The city-based Bharat Biotech International Limited (BBIL), a manufacturer of Hepatitis-B vaccine, is now developing a drug indicated for vascualr angiogenesis in collaboration with Centre for Biochemical tehcnology, New Delhi.

BBIL executives said the basic reason for taking up the new project was the increasing number project was the increasing number of coronary deaths in the country.

They also said that the BBIL had already completed the research and development for manufacturing indigenous plasminogen activator, streptokinase, which is a bio-pharmaceutical drug for the first line management of cardiac failure in patients with myocardial infarction.